Trial Profile
A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Carboplatin; Vinorelbine; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms Lung-TRIO
- 13 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Apr 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Dec 2009 New trial record